Findings of Research Misconduct, 59626-59627 [2017-26961]

Download as PDF 59626 Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices or other forms of information technology to minimize the information collection burden. Amy McNulty, Acting Director, Division of the Executive Secretariat. DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: [FR Doc. 2017–27013 Filed 12–14–17; 8:45 am] ACTION: BILLING CODE 4165–15–P Findings of research misconduct have been made on the part of Matthew Endo, former graduate student, Department of Chemistry, University of Illinois at UrbanaChampaign. The questioned research was supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM080436. The administrative actions, including three (3) years of supervision, which are implemented beginning on November 16, 2017, are detailed below. FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Matthew Endo, University of Illinois at Urbana-Champaign: Based on the Respondent’s admission, an assessment conducted by University of Illinois at Urbana-Champaign (UIUC), and analysis conducted by ORI in its oversight review, ORI found that Mr. Matthew Endo, a former graduate student, Department of Chemistry, UIUC, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grant R01 GM080436. ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly causing false data to be recorded, falsifying and/or fabricating data and related images by alteration and/or reuse and/or relabeling of experimental data, and reporting falsified and/or fabricated data in one (1) manuscript subsequently submitted for publication: • ‘‘Amphotericin primarily kills human cells by binding and extracting cholesterol.’’ Submitted for publication to the Proceedings of the National Academy of Sciences [withdrawn prior to peer review] (hereafter referred to as ‘‘Manuscript 1’’) SUMMARY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination Concerning a Petition To Add a Class of Employees to the Special Exposure Cohort National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS). AGENCY: ACTION: Notice. HHS gives notice of a determination concerning a petition to add a class of employees from the Carborundum Company, in Niagara Falls, New York, to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA). SUMMARY: FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 1–877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV. SUPPLEMENTARY INFORMATION: Authority: [42 U.S.C.7384q]. sradovich on DSK3GMQ082PROD with NOTICES On November 16, 2017, the Acting Secretary of HHS determined that the following class of employees does not meet the statutory criteria for addition to the SEC as authorized under EEOICPA: All employees who worked in any area of the Carborundum Company facility on Buffalo Avenue, Niagara Falls, New York, from January 1, 1943, through December 31, 1976. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2017–27039 Filed 12–14–17; 8:45 am] BILLING CODE 4163–19–P VerDate Sep<11>2014 23:42 Dec 14, 2017 Jkt 244001 Specifically, ORI found that: • In Manuscript 1, Respondent caused falsified and/or fabricated results to PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 be recorded by knowingly requesting biological testing of a mixture of compounds that he falsely claimed to be a single compound • In Manuscript 1, Respondent falsified and/or fabricated the results on page S26 of the Supporting Information by modifying the HPLC trace through peak erasure to make the preparation of C35deOAmB appear more pure than in the actual results of experimentation • In Manuscript 1, Respondent falsified and/or fabricated the results of Surface Plasmon Resonance data on page S7 of the Supporting Information to make the error bars smaller than the actual results of experimentation • In Manuscript 1, Respondent falsified and/or fabricated the results of a WST08 Cell Proliferation Assay on page S32 of the Supporting Information by falsely claiming to run the reaction in triplicate when it was only performed in duplicate • In correspondence with his advisor, Respondent falsified and/or fabricated the results of the preparation of putative C2deoAmB where Respondent modified and relabeled a HPLC trace and relabeled an NMR spectrum to falsely claim characterization, purity, and identification of sample that was sent for biological assay Mr. Endo entered into a Voluntary Settlement Agreement and voluntarily agreed for a period of three (3) years, beginning on November 16, 2017: (1) To have his research supervised; Respondent agreed to ensure that prior to the submission of an application for PHS support for a research project on which Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHSsupported research, the institution employing him must submit a plan for supervision of Respondent’s duties to ORI for approval; the plan for supervision must be designed to ensure the scientific integrity of Respondent’s research contribution; Respondent agreed that he will not participate in any PHS-supported research until a plan for supervision is submitted and approved by ORI; (2) that any institution employing him must submit in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are E:\FR\FM\15DEN1.SGM 15DEN1 Federal Register / Vol. 82, No. 240 / Friday, December 15, 2017 / Notices accurately reported in the application, report, manuscript, or abstract; (3) if no supervisory plan is provided to ORI, to provide certification to ORI on annual basis that he has not engaged in, applied for, or had his name included on any application, proposal, or other request for PHS funds without prior notification to ORI; and (4) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Kathryn M. Partin, Director, Office of Research Integrity. BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination Concerning a Petition To Add a Class of Employees to the Special Exposure Cohort National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS). AGENCY: Notice. HHS gives notice of a determination concerning a petition to add a class of employees from the Rocky Flats Plant, in Golden, Colorado, to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA). SUMMARY: FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 1090 Tusculum Avenue, MS C–46, Cincinnati, OH 45226–1938, Telephone 1–877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV. SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES Authority: [42 U.S.C. 7384q]. On November 16, 2017, the Acting Secretary of HHS determined that the following class of employees does not meet the statutory criteria for addition to the SEC as authorized under EEOICPA: All employees of the Department of Energy, its predecessor agencies, and their contractors and subcontractors who worked in any area of the Rocky Flats Plant in VerDate Sep<11>2014 23:42 Dec 14, 2017 Jkt 244001 John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2017–27040 Filed 12–14–17; 8:45 am] BILLING CODE 4163–19–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. [FR Doc. 2017–26961 Filed 12–14–17; 8:45 am] ACTION: Golden, Colorado, from January 1, 1984, through December 31, 2005. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Pre and Postnatal Neurologic Disorders. Date: December 19, 2017. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, 301–435– 1259, nadis@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: December 12, 2017. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–27108 Filed 12–14–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 59627 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the meeting of the Council of Councils. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting website (http:// videocast.nih.gov). A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Council of Councils. Open: January 26, 2018. Time: 8:15 a.m. to 11:30 a.m. Agenda: Call to Order and Introductions; Announcements and Updates; Common Fund 4D Nucleome Presentation; NIH Update; Common Fund Concepts. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Closed: January 26, 2018. Time: 12:15 p.m. to 1:30 p.m. Agenda: Review of Grant Applications. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Open: January 26, 2018. Time: 1:30 p.m. to 4:00 p.m. Agenda: Tribal Health Research Office Update and Input; Introduction of New Working Group to Council of Councils; Update & Input—Office of Research on Women’s Health Strategic Plan; The ECHO Program at Year One; Closing Remarks. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Franziska Grieder, D.V.M., Ph.D., Executive Secretary, Director, Office of Research Infrastructure Programs, Division of E:\FR\FM\15DEN1.SGM 15DEN1

Agencies

[Federal Register Volume 82, Number 240 (Friday, December 15, 2017)]
[Notices]
[Pages 59626-59627]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26961]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Findings of research misconduct have been made on the part of 
Matthew Endo, former graduate student, Department of Chemistry, 
University of Illinois at Urbana-Champaign. The questioned research was 
supported by National Institute of General Medical Sciences (NIGMS), 
National Institutes of Health (NIH), grant R01 GM080436. The 
administrative actions, including three (3) years of supervision, which 
are implemented beginning on November 16, 2017, are detailed below.

FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim 
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of 
Research Integrity (ORI) has taken final action in the following case:
    Matthew Endo, University of Illinois at Urbana-Champaign: Based on 
the Respondent's admission, an assessment conducted by University of 
Illinois at Urbana-Champaign (UIUC), and analysis conducted by ORI in 
its oversight review, ORI found that Mr. Matthew Endo, a former 
graduate student, Department of Chemistry, UIUC, engaged in research 
misconduct in research supported by National Institute of General 
Medical Sciences (NIGMS), National Institutes of Health (NIH), grant 
R01 GM080436.
    ORI found that Respondent engaged in research misconduct by 
intentionally, knowingly, or recklessly causing false data to be 
recorded, falsifying and/or fabricating data and related images by 
alteration and/or reuse and/or relabeling of experimental data, and 
reporting falsified and/or fabricated data in one (1) manuscript 
subsequently submitted for publication:
 ``Amphotericin primarily kills human cells by binding and 
extracting cholesterol.'' Submitted for publication to the Proceedings 
of the National Academy of Sciences [withdrawn prior to peer review] 
(hereafter referred to as ``Manuscript 1'')

    Specifically, ORI found that:

 In Manuscript 1, Respondent caused falsified and/or fabricated 
results to be recorded by knowingly requesting biological testing of a 
mixture of compounds that he falsely claimed to be a single compound
 In Manuscript 1, Respondent falsified and/or fabricated the 
results on page S26 of the Supporting Information by modifying the HPLC 
trace through peak erasure to make the preparation of C35deOAmB appear 
more pure than in the actual results of experimentation
 In Manuscript 1, Respondent falsified and/or fabricated the 
results of Surface Plasmon Resonance data on page S7 of the Supporting 
Information to make the error bars smaller than the actual results of 
experimentation
 In Manuscript 1, Respondent falsified and/or fabricated the 
results of a WST08 Cell Proliferation Assay on page S32 of the 
Supporting Information by falsely claiming to run the reaction in 
triplicate when it was only performed in duplicate
 In correspondence with his advisor, Respondent falsified and/
or fabricated the results of the preparation of putative C2deoAmB where 
Respondent modified and relabeled a HPLC trace and relabeled an NMR 
spectrum to falsely claim characterization, purity, and identification 
of sample that was sent for biological assay

    Mr. Endo entered into a Voluntary Settlement Agreement and 
voluntarily agreed for a period of three (3) years, beginning on 
November 16, 2017:
    (1) To have his research supervised; Respondent agreed to ensure 
that prior to the submission of an application for PHS support for a 
research project on which Respondent's participation is proposed and 
prior to Respondent's participation in any capacity on PHS-supported 
research, the institution employing him must submit a plan for 
supervision of Respondent's duties to ORI for approval; the plan for 
supervision must be designed to ensure the scientific integrity of 
Respondent's research contribution; Respondent agreed that he will not 
participate in any PHS-supported research until a plan for supervision 
is submitted and approved by ORI;
    (2) that any institution employing him must submit in conjunction 
with each application for PHS funds, or report, manuscript, or abstract 
involving PHS supported research in which Respondent is involved, a 
certification to ORI that the data provided by Respondent are based on 
actual experiments or are otherwise legitimately derived and that the 
data, procedures, and methodology are

[[Page 59627]]

accurately reported in the application, report, manuscript, or 
abstract;
    (3) if no supervisory plan is provided to ORI, to provide 
certification to ORI on annual basis that he has not engaged in, 
applied for, or had his name included on any application, proposal, or 
other request for PHS funds without prior notification to ORI; and
    (4) to exclude himself voluntarily from serving in any advisory 
capacity to PHS including, but not limited to, service on any PHS 
advisory committee, board, and/or peer review committee, or as a 
consultant.

Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017-26961 Filed 12-14-17; 8:45 am]
 BILLING CODE 4150-31-P